Company Overview and News

3
Tetra Bio-Pharma Adds a New Leader for its Commercial Operations

2018-06-19 globenewswire
ORLEANS, Ontario, June 19, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Takes on Fentanyl in Head to Head Trial for the Treatment of Breakthrough Pain

2018-06-18 globenewswire
ORLEANS, Ontario, June 18, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Santé Cannabis, the independently credentialed research organization they work with has finalized the clinical study protocol evaluation of PPP001, which will be the first time that cannabis is being compared to fentanyl in a clinical trial.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Inc. Provides Corporate Update Ahead of Its Annual General Meeting

2018-06-13 globenewswire
ORLEANS, Ontario, June 13, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to provide a Corporate Update on its programs and upcoming milestones in the development of its bio-pharmaceutical and natural health products that address large markets with significant unmet medical needs.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Inc. Clarifies AGM Meeting Location

2018-05-17 globenewswire
ORLEANS, Ontario, May 17, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (OTCQB:TBPMF), wishes to clarify that the annual general meeting of shareholders of the Corporation (the “Meeting”) is to be held in the City of Montréal, Québec. The Corporation noted that the notice of meeting and record date filed under the Corporation’s profile on SEDAR on April 27, 2018 incorrectly stated that the Meeting would be held in the City of Ottawa, Ontario.
TBPMF TBP GRPOF

3
Tetra BioPharma Signs Second Commercialization Deal with Azevedos Industria Farmaceutica, S.A. for the Lead RX product PPP001

2018-05-04 globenewswire
OTTAWA, May 04, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), and Azevedos Indústria Farmacêutica, S.A. announced that they have signed a binding term sheet for the marketing and distribution of PPP001 in Portugal. This binding term sheet will pave the way towards signing a Definitive Distribution Agreement.
TBPMF TBP GRPOF

30
Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel

2018-04-24 marketwired
OTTAWA, ONTARIO--(Marketwired - April 24, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.
TBPMF KMDA TBP GRPOF

9
Tetra Bio-Pharma Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018

2018-04-12 marketwired
OTTAWA, ONTARIO--(Marketwired - April 12, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization.
TBPMF APH APHQF TBP GRPOF

3
Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors

2018-04-10 marketwired
OTTAWA, ONTARIO--(Marketwired - April 10, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of directors effective April 10, 2018.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study

2018-04-04 marketwired
OTTAWA, ONTARIO--(Marketwired - April 4, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Names Guy Chamberland as Interim CEO

2018-04-03 marketwired
OTTAWA, ONTARIO--(Marketwired - April 3, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.
TBPMF TBP GRPOF

3
CORRECTION FROM SOURCE: Tetra Bio-Pharma Inc. Announces the Closing of $4,292,000 Non-Brokered Private Placement

2018-03-28 marketwired
OTTAWA, ONTARIO--(Marketwired - March 27, 2018) - This document corrects and replaces the press release that was sent on March 27, 2018 at 7:30 PM ET.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Inc. Announces the Closing of $4,422,000 Non-Brokered Private Placement

2018-03-27 marketwired
OTTAWA, ONTARIO--(Marketwired - March 27, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has closed its non-brokered private placement of 4,422,000 units at a price of $1.00 per unit for aggregate gross proceeds of $4,422,000. Each unit consists of one common share and one non-transferable warrant, with a warrant entitling the holder to purchase one common share at a price of $1.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Added to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index

2018-03-20 marketwired
OTTAWA, ONTARIO--(Marketwired - March 20, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.

2018-03-19 marketwired
OTTAWA, ONTARIO--(Marketwired - March 19, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the "Transaction") from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the "Sellers").
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement

2018-03-16 marketwired
OTTAWA, ONTARIO--(Marketwired - March 16, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it is conducting a non-brokered private placement of up to 4,500,000 units at a price of $1.00 per unit for aggregate gross proceeds of up to $4,500,000.
TBPMF TBP GRPOF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to CNSX:TBP / Tetra Bio-Pharma Inc. on message board site Silicon Investor.

Telebackup ( TBP ) to blast off! TELEBACK-UP TBP (ASE)